The current stock price of GRAL is 116.06 USD. In the past month the price increased by 23.01%. In the past year, price increased by 305.66%.
ChartMill assigns a technical rating of 10 / 10 to GRAL. When comparing the yearly performance of all stocks, GRAL is one of the better performing stocks in the market, outperforming 98.61% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to GRAL. No worries on liquidiy or solvency for GRAL as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months GRAL reported a non-GAAP Earnings per Share(EPS) of -11.64. The EPS increased by 90.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.62% | ||
| ROE | -18.14% | ||
| Debt/Equity | 0 |
10 analysts have analysed GRAL and the average price target is 107.1 USD. This implies a price decrease of -7.72% is expected in the next year compared to the current price of 116.06.
For the next year, analysts expect an EPS growth of 82.14% and a revenue growth 18.12% for GRAL
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
GRAIL INC
1525 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 1000
Phone: 18336942553
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
The current stock price of GRAL is 116.06 USD. The price increased by 14.83% in the last trading session.
GRAL does not pay a dividend.
GRAL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
GRAL stock is listed on the Nasdaq exchange.
GRAIL INC (GRAL) has a market capitalization of 4.52B USD. This makes GRAL a Mid Cap stock.
You can find the ownership structure of GRAIL INC (GRAL) on the Ownership tab.